Longitudinal mRNA expression analysis of the adaptive response to Enzalutimde in LNCaP cells

The aim of this study is to investigate metabolic alterations involved in the adaptive response of prostate cancer cells to androgen-deprivation therapy (ADT) and AR-targeted therapies (ATTs) in hopes of identifying novel targets to help delay progression to castrate-resistant prostate cancer (CRPC). We developed an in vitro model of long-term ATT and used transcriptomics, proteomics and lipidomics to identify metabolic pathways contributing to cell survival. LNCaP cells were treated for up to 21 days with 10 µM Enzalutamide (ENZ) in DMSO (vehicle control). Samples were collected on day 0 (DMSO control), 7, 14 and 21. 3 biological repeats of each sample were processed for microarray analysis.